Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
9,445,037
-
Share change
-
-309,821
-
Total reported value
-
$11,901,089
-
Put/Call ratio
-
25%
-
Price per share
-
$1.26
-
Number of holders
-
61
-
Value change
-
-$599,933
-
Number of buys
-
23
-
Number of sells
-
30
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q1 2024
As of 31 Mar 2024,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,445,037 shares.
The largest 10 holders included
BlackRock Inc., STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, GSA CAPITAL PARTNERS LLP, NORTHERN TRUST CORP, VANGUARD GROUP INC, Nuveen Asset Management, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, and Bank of New York Mellon Corp.
This page lists
62
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.